Igenomix India +91 11 6651 7800 info.india@igenomix.com


Early risk detection of hereditary breast and ovarian cancer

1.What is the Oncodona Test?

Oncodona is a complete test of genetic screening that analyzes 21 genes related to breast and ovarian cancer.

It is the most advanced genetic test for early identification of predisposition to inherited cancer. Oncodona uses Next Generation Sequencing (NGS) to analyze genetic information present in a panel of 21 genes, including BRCA1 and BRCA2 genes, in order to locate harmful mutations.
The presence of a change or mutation in one of these genes suggests that the female carrier has an increased risk of developing breast and ovarian tumours, or other related cancers.

2. What genes are included in the Oncodona test?

In addition to the BRCA1 and BRCA2 genes, the Oncodona test analyzes 19 more genes associated with risk of breast and ovarian cancer, which makes it a more complete test:
Table oncodona

3. What are the BRCA1 and BRCA2 genes?

The risk for a woman of getting breast or ovarian cancer, as well as other related cancers, increases signficantly if she inherits a damaging mutation in the BRCA1 or BRCA2 gene.

The BRCA1 and BRCA2 genes are the two most important genes related to the development of hereditary breast and ovarian cancer. These genes produce proteins that help repair cell damage. If one of these genes has a mutation or alteration, the repair function of the protein is deficient or absent. This leads to a greater probability of accumulating new genetic alterations that can bring about the development of a tumor.

The presence of mutations in BRCA1 or BRCA2 genes are 20-fold higher in women with precocious breast cancer diagnosed before age 40. Mutations in BRCA1 and BRCA2 account for approximately 5% of all breast cancers and between 10-15% of ovarian cancers.

4. Why take the IGENOMIX Oncodona Test?

Oncodona personas
A positive test result may also have important health implications for family members, and even for future generations.

In the case of patients diagnosed with breast cancer and BRCA1 and BRCA2 negative genetic test, Oncodona can find a mutation in up to 4% of women.

The performance of the test, if positive, can be used to adopt follow-up and personalized early detection measures of the patient and their relatives.
• Carriers already diagnosed will be more likely to have another type of cancer. In these cases it is essential to perform intensive tests that can locate a cancer in its early stages, when the probability that it will be successfully treated is greater.
• In the case of people with mutations, there are several preventive options to deal with the cancer risk. These measures include intensified screening for early diagnosis.

When a mutation is detected in a family member, there is an increased risk that other members of the family will be carriers of the same mutation.

• People who inherit harmful mutations can transmit these mutations to their sons and daughters with a 50% probability.
• If a person has inherited a harmful mutation, it means that each of their brothers or sisters has a 50% chance of inheriting that mutation.

5. Who should do the test?


The Oncodona test offers genetic counselling by expert staff.

Oncodona is a simple and complete test for all women who want to have the maximum information about their personal risk of developing cancer.
The information provided by Oncodona allows you to customize the breast and ovarian cancer prevention programme. It is suitable for:

• Women diagnosed with breast cancer and BRCA1 and BRCA2 negative genetic test. In this type of patients Oncodona can find a mutation in up to 4% of women.
• Women with a family member diagnosed with breast and ovarian cancer.
• Women of general population without known increased risk.

6. How to perform the test?

Time of delivery of results: 30 days